about
Markedly increased volume of distribution of gadolinium in cardiac amyloidosis demonstrated by T1 mappingCardiovascular magnetic resonance imaging of myocardial infarction, viability, and cardiomyopathies.Advances in Cardiovascular MRI for Diagnostics: Applications in Coronary Artery Disease and CardiomyopathiesCardiac sarcoidosis: case report, workup, and review of the literature.Comprehensive cardiac magnetic resonance imaging.Investigation of cardiomyopathy using cardiac magnetic resonance imaging part 1: Common phenotypes.Uncharted waters: rare and unclassified cardiomyopathies characterized on cardiac magnetic resonance imagingCardiac MRI in infiltrative disorders: a concise reviewNephrotic syndrome: A twist in the tail.Cardiac amyloidosis responding to bortezomib: case report and review of literature.Myocardial Deformation in Cardiac Amyloid Light-chain Amyloidosis: Assessed with 3T Cardiovascular Magnetic Resonance Feature Tracking.Systemic Al amyloidosis of the tracheobronchial tract and lungs: a rare finding.Guideline of transthyretin-related hereditary amyloidosis for clinicians.A case of cardiac amyloidosis with diuretic-refractory pleural effusions treated with bevacizumabTransthyretin cardiac amyloidoses in older North Americans.Heart transplantation and end-stage cardiac amyloidosis: a review and approach to evaluation and management.Al amyloidosisTransthyretin (TTR) cardiac amyloidosis.Parenchymal signal intensity in 3-T body MRI of dogs with hematopoietic neoplasia.Circulating matrix metalloproteinases and tissue inhibitors of metalloproteinases in cardiac amyloidosis.Canadian Cardiovascular Society Consensus Conference guidelines on heart failure--2008 update: best practices for the transition of care of heart failure patients, and the recognition, investigation and treatment of cardiomyopathiesIncidence of supraventricular arrhythmias during autologous peripheral blood stem cell transplantation.Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in light-chain cardiac amyloidosisApplication of cardiac magnetic resonance imaging in cardiomyopathyMatrix metalloproteinases and their tissue inhibitors in cardiac amyloidosis: relationship to structural, functional myocardial changes and to light chain amyloid deposition.Cardiac magnetic resonance imaging of systemic amyloidosis patients with normal left ventricular ejection fraction: An initial study.Amyloid and the GI tract.Advanced cardiac amyloidosis associated with normal interventricular septal thickness: an uncommon presentation of infiltrative cardiomyopathy.Cardiac amyloidosis: an approach to diagnosis and management.The role of cardiac magnetic resonance imaging in the assessment of non-ischemic cardiomyopathy.Role of echocardiography in cancer care.Cardiac involvement in hereditary-transthyretin related amyloidosis.Heart muscle disease and cardiovascular magnetic resonance imaging.Natural history and therapy of AL cardiac amyloidosis.Outcomes after heart transplantation for amyloid cardiomyopathy in the modern era.A Plasma Cell Dyscrasia Presenting as Amyloid Cardiomyopathy and Autonomic Dysfunction in a Healthy Patient.Use of Noninvasive Imaging in Cardiac Amyloidosis.Heart transplantation in cardiac amyloidosis.Cardiac magnetic resonance imaging in heart failure: where the alphabet begins!Focal monomorphic ventricular tachycardia as the first manifestation of amyloid cardiomyopathy.
P2860
Q30409332-02AAD286-D9DC-454D-96F6-5D17EDC026C2Q30432814-FE46EA31-E72D-4C8D-8A49-15CCC463EEECQ30434105-0D37FCE5-DAA7-4FEB-B8A5-B4DCB633194EQ30434303-14C9656A-8772-45AC-A37A-403F3D04D437Q30434419-41CB33D6-3C32-4B71-8020-93B1FA52AE3FQ30467896-8DD83173-4BFB-4EB9-8722-B1C428321EDFQ30470370-6B75E6B4-356D-40C8-B7F9-AA499B1ABA2CQ30475624-E8771EF5-C6ED-43CD-BE2F-EFB41C837BEDQ33619202-B69D885D-4FC3-4F27-AA20-61476934EB48Q33654026-0AF0CB7B-2207-4341-983C-21C70737B20DQ33812497-56322C79-ADE0-452A-8E8C-EADAED35E923Q34126583-CAC1FDBA-9ADF-48E5-B55B-CCB341567B0EQ34328734-EFE8F88B-0DE4-4380-BF13-32914B8A2F30Q34512589-5CD3B303-D696-4B90-B0EF-D4CD427FC00DQ35886169-0A9E2BFF-4A36-4CC4-AF14-B8CD0B68AF44Q36367005-118E1FD7-DF8D-47A2-B704-2A79E3F42A23Q36392233-A149A027-37E3-4A4B-B3AD-59C973CAC7FCQ36408438-00922BA2-B5D4-471C-A141-87C14D919848Q36762017-2D639C00-6E11-40CD-9239-407EAED39B0AQ36824706-0AB83A32-7B68-4E49-AF61-6A524FD7F0CCQ37061992-C3D5E189-5392-4F3E-B8E9-66BAF66EEBEFQ37118014-18366390-E991-420C-A1FC-9691C2DD8BCCQ37186950-8E9D6EAA-286E-4810-90B8-CB32066228ECQ37254551-29921845-146C-486C-8999-285EC3787519Q37414489-23F89296-E795-4A38-9791-F584A0D7AA20Q37527009-A3E9C623-2933-4D04-A758-88AF8239F46CQ37636098-C97E2ECB-4F20-4562-9C3E-5532D3D9EFE9Q37678566-ECF0614F-6B42-40A3-884D-E91502652064Q37770112-3D976F1B-9FCA-419E-A44F-883631209319Q37822294-B9E0B73E-75CB-4512-8E6E-D116CC490CAFQ37874172-EF4413BA-BD09-4724-A856-ED3EA221AE72Q38001756-71BFEB16-5671-4D0E-B33F-76873B9151B9Q38231508-1F5F20B9-57FC-468C-AE36-79E54BC1EB59Q38275212-D8B355CB-9066-47C5-A47B-FCD75A21BAD6Q38343098-00EFB57E-8AD6-45F2-9DC8-D7F3D503B8CBQ38634630-2DA07DCA-AE17-4EF3-9F24-CD8911D16C6EQ38834998-282D0273-D1E4-4ADB-836E-38D1676B47E2Q39172346-C9EAA3E8-6796-4AB2-89C2-D407F4A19D18Q39255836-CE8CE82F-F378-43B5-9D06-1CED692321FDQ39439857-B65DF824-4E80-4EB6-AF79-CC3742984839
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Evaluation and management of the cardiac amyloidosis.
@en
Evaluation and management of the cardiac amyloidosis.
@nl
type
label
Evaluation and management of the cardiac amyloidosis.
@en
Evaluation and management of the cardiac amyloidosis.
@nl
prefLabel
Evaluation and management of the cardiac amyloidosis.
@en
Evaluation and management of the cardiac amyloidosis.
@nl
P2093
P1476
Evaluation and management of the cardiac amyloidosis
@en
P2093
Joseph B Selvanayagam
Philip N Hawkins
Stefan Neubauer
P304
P356
10.1016/J.JACC.2007.08.028
P407
P50
P577
2007-11-13T00:00:00Z